ProMIS Neurosciences Granted US Patent 12,071,472 For "Methods Of Reducing Toxicity Induced By Amyloid Beta Oligomers Using Antibodies Specific To A-Beta Oligomers" In Alzheimer's Treatment
Portfolio Pulse from Benzinga Newsdesk
ProMIS Neurosciences has been granted a US patent for methods of reducing toxicity induced by amyloid beta oligomers using specific antibodies in Alzheimer's treatment. This patent could enhance their position in the Alzheimer's treatment market.
August 27, 2024 | 6:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ProMIS Neurosciences has received a US patent for a method to reduce toxicity in Alzheimer's treatment, potentially boosting its market position.
The granting of a US patent for a novel Alzheimer's treatment method is a significant milestone for ProMIS Neurosciences. It strengthens their intellectual property portfolio and could enhance their competitive edge in the Alzheimer's treatment market, likely leading to positive investor sentiment and a potential increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100